World's Best Scientists 2026 revealed!
Franck Morschhauser

Franck Morschhauser

D-Index & Metrics

Medicine

D-Index
94
Citations
37993
World Ranking
10371
National Ranking
323

Overview

Franck Morschhauser is affiliated with the University of Lille in France. Their research primarily focuses on fields within medicine, with notable contributions in pathology and forensic medicine, oncology, genetics, molecular biology, and immunology.

The scientist's work extensively covers several specialized topics, including:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Viral-associated cancers and disorders
  • CNS Lymphoma Diagnosis and Treatment
  • Cutaneous lymphoproliferative disorders research
  • Monoclonal and Polyclonal Antibodies Research

Franck Morschhauser has published papers in some of the leading oncology and hematology journals. Frequent venues for their publications include:

  • Blood
  • Hematological Oncology
  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances

Co-authorship is a significant element in their research output. Key frequent co-authors are:

  • Emmanuel Bachy
  • Guillaume Cartron
  • Olivier Casasnovas
  • Catherine Thiéblemont
  • Roch Houot

Among notable papers authored or co-authored by Franck Morschhauser are:

  • "The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee" (2022, Blood)
  • "Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial" (2022, The Lancet)
  • "Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma" (2022, New England Journal of Medicine)
  • "Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial" (2020, The Lancet Oncology)
  • "Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma" (2021, New England Journal of Medicine)

Best Publications

  • Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

    P Feugier;A. Van Hoof;C. Sebban;P. Solal-Celigny

  • Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

    Bertrand Coiffier;Barbara Pro;H. Miles Prince;Francine Foss

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

    Franck Morschhauser;John Radford;Achiel Van Hoof;Umberto Vitolo

  • Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

    Gilles Salles;Nicolas Mounier;Sophie de Guibert;Franck Morschhauser

  • Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

    Sylvain Choquet;Veronique Leblond;Raoul Herbrecht;Gérard Socié

  • Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial

    Ralf Trappe;Stephan Oertel;Veronique Leblond;Peter Mollee

  • Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

    Arnaud Jaccard;Nathalie Gachard;Benoit Marin;Sylvie Rogez

  • Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

    Michael Wang;Simon Rule;Pier Luigi Zinzani;Andre Goy

  • Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

    Franck Morschhauser;Hervé Tilly;Aristeidis Chaidos;Pamela McKay

  • Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

    Sandy Amorim;Anastasios Stathis;Mary Gleeson;Sunil Iyengar

  • Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

    Steven Le Gouill;Catherine Thieblemont;Lucie Oberic;Anne Moreau

  • Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

    Martin Dreyling;Armando Santoro;Luigina Mollica;Sirpa Leppä

  • Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

    Maria Corinna A Palanca-Wessels;Myron Czuczman;Gilles Salles;Sarit Assouline

  • Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

    Anas Younes;Catherine Thieblemont;Franck Morschhauser;Ian Flinn

  • Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

    John G. Gribben;Nathan Fowler;Franck Morschhauser

  • Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

    Franck Morschhauser;Nathan Fowler;Pierre Feugier;Reda Bouabdallah

  • SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

    René-Olivier Casasnovas;Michel Meignan;Alina Berriolo-Riedinger;Stéphane Bardet

  • A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

    Harriet S. Walter;Simon A. Rule;Martin J. S. Dyer;Lionel Karlin

  • Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

    Christian Récher;Bertrand Coiffier;Corinne Haioun;Thierry Jo Molina

Frequent Co-Authors

Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
John Radford
John Radford University of Manchester
Ryan D. Morin
Ryan D. Morin Simon Fraser University
Ranjana H. Advani
Ranjana H. Advani Stanford University
Raoul Herbrecht
Raoul Herbrecht University of Strasbourg
Pauline Brice
Pauline Brice Hôpital Saint-Louis
Peter Johnson
Peter Johnson University of Southampton
Eric Oksenhendler
Eric Oksenhendler Université Paris Cité
Olivier Casasnovas
Olivier Casasnovas Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in Medicine but want to explore alternative or supporting careers in healthcare, several online degree programs offer flexible and affordable options. These pathways can provide valuable credentials and open doors to essential medical roles.

For those drawn to the data side of healthcare, pursuing an online mhi (Master’s in Health Information) degree is a great step. This field focuses on managing patient data and health information systems.

Students seeking entry-level roles should consider affordable medical billing and coding programs. These programs prepare you for fast-growing jobs handling crucial administrative functions in medical settings.

For those interested in nursing careers, you’ll find a range of cheap online nursing programs for RN degrees. If you want to advance and become a nurse practitioner, check out the cheapest online fnp program options for a graduate degree.

These related online programs make it easier to progress in healthcare—no matter your background or budget.

Best Scientists Citing Franck Morschhauser

Trending Scientists